Among people with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was associated with a reduced risk of major kidney events compared with dulaglutide, primarily driven by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results